Staff editor
Microbiomepost conducted an exclusive interview with George Paraskevakos, Executive Director at International Probiotic Association in order to discuss the global market of biotic products in 2025.
Ger T. Rijkers, University College Roosevelt, Netherlands, discusses the regulatory frame about probiotics in Europe.
Douwe Van Sinderen, professor of Molecular Microbiology at School of Microbiology & APC Microbiome Ireland, focuses on bacteriophages infecting lactic acid bacteria used in food and probiotic applications.
Immunology
Sponsored by
Three infant-derived strains isolated and developed by Coree srl that are potentially interesting for immune support.
Emilia Ghelardi, Professor of Microbiology and Molecular Microbiology at the University of Pisa, explains how pathogens can actively disrupt the integrity of the commensal community.
Arthur Ouwehand, Technical Fellow at IFF Finland, discusses the components and vulnerabilities of the gut barrier and reviews how probiotics and related dietary interventions can support its structure and function.
MaaT Pharma, based in Lyon and listed on Euronext Paris, unveiled the final results of its ARES Phase 3 trial of Xervyteg® (MaaT013).
Akari Hiraku, researcher at Innovative Research Institute, Morinaga Milk Industry Co., presented clinical data on Bifidobacterium longum subsp. infantis M-63, a probiotic strain with a remarkable capacity to utilize HMOs.
2 December event in Brussels will unveil new socio-economic analysis on how clearer EU rules for probiotics could cut healthcare costs, drive innovation and strengthen the single market.
Pediatrics, Industry
Sponsored by
Bifidobacterium breve 2TA, Lacticaseibacillus rhamnosus L13B, and Lactobacillus gasseri L6 are not just bacteria: they are witnesses to the intimate, ancestral dialogue between mothers, infants, and microbes.
